Palvella Therapeutics (PVLA) Revenue (2014 - 2024)
Palvella Therapeutics (PVLA) reported Revenue of $53000.0 for Q1 2024, down 97.26% year-over-year from $1.9 million in Q2 2023, and down 99.66% on a QoQ basis from $15.6 million in Q3 2023.
Palvella Therapeutics (PVLA) has 11 years of Revenue data on file, last reported at $53000.0 in Q1 2024.
- Quarterly Revenue fell 97.26% year-over-year to $53000.0 in Q1 2024, while the trailing twelve-month figure through Sep 2024 was $15.6 million (down 58.69% YoY) and the FY2021 annual result came in at $27.9 million, down 4.72% from the prior year.
- Revenue declined to $53000.0 in Q1 2024 per PVLA's latest filing, from $15.6 million in the prior quarter.
- Across five years, Revenue topped out at $20.1 million in Q2 2023 and bottomed at $53000.0 in Q1 2024.
- The 5-year median for Revenue is $3.5 million (2022), against an average of $7.0 million.
- The widest annual swing landed in 2023, when Revenue jumped 5934.5%; it then sank 97.26% in 2024.
- Tracing PVLA's Revenue over 5 years: stood at $1.9 million in 2020, then surged by 164.52% to $5.0 million in 2021, then tumbled by 94.8% to $258000.0 in 2022, then jumped by 5934.5% to $15.6 million in 2023, then tumbled by 99.66% to $53000.0 in 2024.
- Per Business Quant, the three latest PVLA Revenue figures stand at $53000.0 (Q1 2024), $15.6 million (Q3 2023), and $20.1 million (Q2 2023).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 306.30 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 2.99 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 3.61 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 1.17 Bn |
| 10 | Palvella Therapeutics | 1.47 Bn | 1.21 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2024 | 53,000.00 |
| Sep 30, 2023 | 15.57 Mn |
| Jun 30, 2023 | 20.06 Mn |
| Mar 31, 2023 | 1.94 Mn |
| Sep 30, 2022 | 258,000.00 |
| Jun 30, 2022 | 3.47 Mn |
| Mar 31, 2022 | 10.99 Mn |
| Dec 31, 2021 | 4.97 Mn |
| Sep 30, 2021 | 2.78 Mn |
| Jun 30, 2021 | 2.54 Mn |
| Mar 31, 2021 | 13.00 Mn |
| Dec 31, 2020 | 1.88 Mn |
| Sep 30, 2020 | 2.94 Mn |
| Jun 30, 2020 | 11.25 Mn |
| Mar 31, 2020 | 13.26 Mn |
| Dec 31, 2019 | 3.06 Mn |
| Sep 30, 2019 | 15.13 Mn |
| Jun 30, 2019 | 5.33 Mn |
| Mar 31, 2019 | 8.55 Mn |
| Dec 31, 2018 | 600,000.00 |
| Sep 30, 2018 | 8.35 Mn |
| Jun 30, 2018 | 11.69 Mn |
| Mar 31, 2018 | 4.15 Mn |
| Dec 31, 2017 | 18.15 Mn |
| Sep 30, 2017 | 3.93 Mn |
| Jun 30, 2017 | 1.85 Mn |
| Mar 31, 2017 | 1.34 Mn |
| Dec 31, 2016 | 2.73 Mn |
| Sep 30, 2016 | 785,007.00 |
| Jun 30, 2016 | 1.07 Mn |
| Mar 31, 2016 | 1.25 Mn |
| Dec 31, 2015 | -423,274.00 |
| Sep 30, 2015 | 414,610.00 |
| Jun 30, 2015 | 160,244.00 |
| Mar 31, 2015 | 217,621.00 |
| Sep 30, 2014 | 18,724.00 |
| Jun 30, 2014 | 698,227.00 |